Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

ConditionsLeukemia, Acute MDS

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age60+

SponsorAbramson Cancer Center at Penn Medicine

About this trial

The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.

Eligibility criteria

Qualifiers

Age 60 years or older.

New diagnosis of Acute Leukemia or MDS, or suspected diagnosis.

Able to consent to the study.

Age 60 years or older with a hematologic malignancy.

Disqualifiers

None

Trial design

Treatments tested in this trial

Bone Marrow or Peripheral Blood Graft (BMT)
Cancer-directed Therapy or Best Supportive Care
Frailty Assessment

Treatment groups

20 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Abramson Cancer Center at Penn Medicine

Lead sponsor

Source ClinicalTrials.gov